在心房动和甲状腺功能障碍患者中,NOACs与华法林对比
Lian Tan1, Jie Feng2, Biao Xiong2
1Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Medicine
|July 15, 2025
概括
非维生素K对抗剂口服抗凝剂 (NOACs) 在患有甲状腺功能障碍的心房动 (AF) 患者中,与华法林相比,显示出更高的长期存活率. 对于那些体重指数低于24公斤/米2的人来说,NOAC特别有益.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗凝药治疗对于预防心房动 (AF) 患者中风至关重要.
- 华法林是一种传统的抗凝剂,具有局限性,包括狭窄的治疗范围和频繁的监测需求.
- 甲状腺功能障碍 (甲状腺功能障碍/甲状腺功能障碍) 影响凝血,影响血栓形成和出血风险.
研究的目的:
- 为了比较非维生素K对抗剂口服抗凝剂 (NOACs) 与甲状腺功能障碍AF患者的华法林的安全性和有效性.
- 评估临床失败复合终点,包括死亡率,中风和严重出血.
主要方法:
- 在中国的两个学术医疗中心进行的回顾性研究.
- 包括18岁以上的AF和甲状腺功能异常的NOAC或华法林开始治疗的患者.
- 基线特征和死亡率,中风和主要出血事件的复合终点的比较.
主要成果:
- 分析了137名患者 (86名NOAC,51名华法林);华法林组患有慢性心力衰竭和CHA2DS2-VASc评分的患病率更高.
- 与华法林相比,NOACs显示复合终点的估计3年生存率显著更高.
- 体重指数<24kg/m2的患者面临更高的终点事件风险.
结论:
- 在患有甲状腺功能障碍的AF患者中,NOACs在长期存活方面似乎优于华法林.
- NOACs的益处在体重指数<24 kg/m2的患者中尤为明显.
- 这表明NOAC在这个特定的患者群体中是一个潜在的更安全和更有效的选择.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.8K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1000
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1000
Anticoagulant Drugs: Low-Molecular-Weight Heparins
917
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
917
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
861
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
861


